Insulin-like growth factors and ovarian cancer risk: A nested case-control study in three cohorts

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 8, 2007, Pages 1691-1695

  Tworoger, Shelley S ^a,b,d   Lee, I Min ^a,b   Buring, Julie E ^a,b   Pollak, Michael N ^c   Hankinson, Susan E ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NURSE; OVARY CANCER; PRIORITY JOURNAL; RISK FACTOR; WOMEN'S HEALTH;

ADULT; AGE FACTORS; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; OVARIAN NEOPLASMS; POSTMENOPAUSE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 34548094011     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0319     Document Type: Article

References (25)

1. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215-44.
2. Resnicoff M, Ambrose D, Coppola D, Rubin R. Insulin-like growth factor-1 and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines. Lab Invest 1993;69:756-60.
3. Lukanova A, Lundin E, Toniolo P, et al. Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer 2002;101:549-54.
4. Peeters PH, Lukanova A, Allen N, et al. Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2007;14:81-90.
5. Baron-Hay S, Boyle F, Ferrier A, Scott C. Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res 2004;10:1796-806.
6. Dal Maso L, Augustin LS, Franceschi S, et al. Association between components of the insulin-like growth factor system and epithelial ovarian cancer risk. Oncology 2004;67:225-30.
7. Flyvbjerg A, Mogensen O, Mogensen B, Nielsen OS. Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab 1997;82:2308-13.
8. Karasik A, Menczer J, Pariente C, Kanety H. Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab 1994;78:271-6.
9. Shah NG, Bhatavdekar JM, Doctor SS, Suthar TP, Balar DB, Dave RS. Circulating epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I) in patients with epithelial ovarian carcinoma. Neoplasma 1994;41:241-3.
10. Waksmanski B, Dudkiewicz J, Kowalski T. Changes in insulin-like growth factor I, 17-β-estradiol, and progesterone in postmenopausal women with benign and malignant ovarian tumours. Med Sci Monit 2001;7:919-23.
11. Chakrabarty S, Kondratick L. Insulin-like growth factor binding protein-2 stimulates proliferation and activates multiple cascades of the mitogen-activated protein kinase pathways in NIH-OVCAR3 human epithelial ovarian cancer cells. Cancer Biol Ther 2006;5:189-97.
12. Kanety H, Kattan M, Goldberg I, et al. Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid. Br J Cancer 1996;73:1069-73.
13. Lee EJ, Mircean C, Shmulevich I, et al. Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer 2005;4:7.
14. Lukanova A, Lundin E, Micheli A, et al. Risk of ovarian cancer in relation to prediagnostic levels of C-peptide, insulin-like growth factor binding proteins-1 and -2 (USA, Sweden, Italy). Cancer Causes Control 2003;14:285-92.
15. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-9.
16. Tworoger SS, Sluss P, Hankinson SE. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 2006;66:2476-82.
17. Tworoger SS, Lee IM, Buring J, Rosner B, Hollis B, Hankinson SE. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007;16:783-8.
18. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:47-55.
19. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:56-65.
20. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304.
21. Hankinson SE, Willett WC, Michaud DS, et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91:629-34.
22. Rosner B. Percentage points for a generalized ESD many-outlier procedure. Technometrics 1983;25:165-72.
23. Yakar S, Pennisi P, Wu Y, Zhao H, LeRoith D. Clinical relevance of systemic and local IGF-I. Endocr Dev 2005;9:11-6.
24. Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE. Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomarkers Prev 2006;15:972-8.
25. Muti P, Quattrin T, Grant BJ, et al. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2002;11:1361-8.